Elsevier

Therapies

Volume 77, Issue 4, July–August 2022, Pages 453-460
Therapies

Pharmacoepidemiology
A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients

https://doi.org/10.1016/j.therap.2021.10.006Get rights and content

Summary

Background and objectives

A notable proportion of COVID-19 patients need statins for their co-existing conditions. Statins possess several anti-inflammatory properties. We have attempted to describe potential association of exposure to statins and severity of COVID symtpoms in a historical study in hospitalized COVID-19 patients.

Methods

This single-center, historical cohort study was performed in Baharloo hospital as a referral hospital for COVID-19 patients in Tehran. Patients were divided into two groups; 163 statins users and 547 non-users. Mortality rate, intensive care unit (ICU) admission and length of hospitalization were compared between studied groups. In addition, during the investigation, pre-existing conditions were evaluated for groups. If a significant difference was observed between groups, the feature was considered in the adjustment of the odds ratio.

Results

At the beginning, statistical analysis study showed that statins users had significantly (p < 0.0001) higher mortality rate, ICU admission and length of hospitalization. But after implementation of variables such as age, sex, diabetes, hypertension status, stroke, dyslipidemia, cardiovascular diseases, chronic kidney disease (CKD), corticosteroids, renin-angiotensin-aldosterone axis inhibitors and proton pump inhibitors (PPIs) for adjustment of the odds ratio, a considerable alteration appeared in the studied values. Following adjustment of odds ratio it was shown that statins did not change mortality (95% CI, OR 0.71 (0.41–1.22), p = 0.22), ICU admission (95% CI, OR 1.05 (0.66–1.66), p = 0.835) and length of hospitalization (95% CI, OR 1.30 (0.78–2.17), p = 0.311). In addition, we found that statins could not decrease inflammatory markers in COVID-19 infected patients.

Conclusion

The use of statins did not seem to change outcomes in COVID19.

Keywords

Statins
COVID-19
Statistics
SARS-CoV-2
Mortality
ICU admission

Cited by (0)

View Abstract